indicatedFor
P23162
predicate
Indicates...that one entity (typically a treatment, procedure, or product) is recommended or appropriate for use in relation to another entity (such as a condition, symptom, or patient group).
All labels observed (17)
| Label | Occurrences |
|---|---|
| indicatedFor canonical | 186 |
| isIndicatedFor | 48 |
| developedForIndication | 8 |
| encouragedFor | 8 |
| EpidiolexIndication | 6 |
| prescribedFor | 6 |
| hasPediatricIndicationFor | 2 |
| indicationContext | 2 |
| isIndicatedAs | 2 |
| isIndicatedIn | 2 |
| originalIndication | 2 |
| PadcevIndication | 1 |
| indicatedForUseIn | 1 |
| indicationCategory | 1 |
| isIndicatedForPopulation | 1 |
| isIndicatedForUseWith | 1 |
| typicallyConsideredFor | 1 |
Sample triples (278)
| Subject | Object |
|---|---|
| Leqembi | early-stage Alzheimer’s disease ⓘ |
| Spinraza | pediatric patients with spinal muscular atrophy ⓘ |
| Spinraza | adult patients with spinal muscular atrophy ⓘ |
| Vumerity | relapsing forms of multiple sclerosis ⓘ |
| Vumerity | relapsing-remitting multiple sclerosis ⓘ |
| Vumerity | active secondary progressive multiple sclerosis ⓘ |
| Vumerity | clinically isolated syndrome ⓘ |
| Eisai | Lecanemab – Alzheimer’s disease via predicate surface "developedForIndication" ⓘ |
| Eisai |
Leqembi
via predicate surface "developedForIndication"
ⓘ
surface form:
Leqembi – Alzheimer’s disease
|
| Eisai |
Donepezil
via predicate surface "developedForIndication"
ⓘ
surface form:
Donepezil – Alzheimer’s disease
|
| Eisai | Aricept – Alzheimer’s disease via predicate surface "developedForIndication" ⓘ |
| Fampyra | multiple sclerosis ⓘ |
| Fampyra | impaired walking in multiple sclerosis ⓘ |
| Xolair | patients with positive skin test or in vitro reactivity to a perennial aeroallergen ⓘ |
| Xolair | patients with inadequately controlled moderate to severe persistent asthma ⓘ |
| Xolair | patients with chronic spontaneous urticaria refractory to H1-antihistamine treatment ⓘ |
| Darzalex | multiple myeloma ⓘ |
| Darzalex | relapsed multiple myeloma ⓘ |
| Darzalex | refractory multiple myeloma ⓘ |
| Darzalex | newly diagnosed multiple myeloma ⓘ |
| Herceptin | adjuvant therapy via predicate surface "isIndicatedAs" ⓘ |
| Herceptin | neoadjuvant therapy via predicate surface "isIndicatedAs" ⓘ |
| Rituxan | non-Hodgkin lymphoma ⓘ |
| Rituxan | diffuse large B-cell lymphoma ⓘ |
| Rituxan | follicular lymphoma ⓘ |
| Rituxan | chronic lymphocytic leukemia ⓘ |
| Rituxan | rheumatoid arthritis ⓘ |
| Rituxan | granulomatosis with polyangiitis ⓘ |
| Rituxan | microscopic polyangiitis ⓘ |
| Rituxan | pemphigus vulgaris ⓘ |
| Activase | acute ischemic stroke ⓘ |
| Activase | acute myocardial infarction ⓘ |
| Activase | ST-elevation myocardial infarction ⓘ |
| Activase | pulmonary embolism ⓘ |
| Activase | acute massive pulmonary embolism ⓘ |
| Activase | restoration of function to occluded central venous access devices ⓘ |
| Stelara | adults via predicate surface "isIndicatedIn" ⓘ |
| Stelara | pediatric patients via predicate surface "isIndicatedIn" ⓘ |
| Stelara | plaque psoriasis via predicate surface "hasPediatricIndicationFor" ⓘ |
| Stelara | psoriatic arthritis via predicate surface "hasPediatricIndicationFor" ⓘ |
| CBD | Dravet syndrome via predicate surface "EpidiolexIndication" ⓘ |
| CBD | Lennox-Gastaut syndrome via predicate surface "EpidiolexIndication" ⓘ |
| CBD | tuberous sclerosis complex–associated seizures via predicate surface "EpidiolexIndication" ⓘ |
| rVSV-ZEBOV | individuals at risk of exposure to Ebola virus ⓘ |
| mAb114 | treatment of infection caused by Zaire ebolavirus ⓘ |
| mAb114 | treatment of Ebola virus disease in adults ⓘ |
| mAb114 | treatment of Ebola virus disease in children ⓘ |
| rivastigmine | mild to moderate Alzheimer’s disease dementia ⓘ |
| rivastigmine | mild to moderate dementia associated with Parkinson’s disease ⓘ |
| Liturgy of the Hours | lay people via predicate surface "encouragedFor" ⓘ |